- Home
- AYTU vs ICU Comparison
AYTU vs ICU Comparison
Compare AYTU & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- ICU
- Stock Information
- Founded
- AYTU N/A
- ICU 2018
- Country
- AYTU United States
- ICU United States
- Employees
- AYTU N/A
- ICU N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- ICU Health Care
- Exchange
- AYTU Nasdaq
- ICU Nasdaq
- Market Cap
- AYTU 19.7M
- ICU 20.3M
- IPO Year
- AYTU N/A
- ICU N/A
- Fundamental
- Price
- AYTU $2.20
- ICU $0.80
- Analyst Decision
- AYTU Strong Buy
- ICU
- Analyst Count
- AYTU 2
- ICU 0
- Target Price
- AYTU $10.00
- ICU N/A
- AVG Volume (30 Days)
- AYTU 109.6K
- ICU 1.9M
- Earning Date
- AYTU 09-25-2025
- ICU 08-13-2025
- Dividend Yield
- AYTU N/A
- ICU N/A
- EPS Growth
- AYTU N/A
- ICU N/A
- EPS
- AYTU N/A
- ICU N/A
- Revenue
- AYTU $81,659,000.00
- ICU $766,000.00
- Revenue This Year
- AYTU N/A
- ICU $754.07
- Revenue Next Year
- AYTU $1.05
- ICU $100.09
- P/E Ratio
- AYTU N/A
- ICU N/A
- Revenue Growth
- AYTU 0.41
- ICU N/A
- 52 Week Low
- AYTU $0.95
- ICU $0.31
- 52 Week High
- AYTU $2.85
- ICU $6.65
- Technical
- Relative Strength Index (RSI)
- AYTU 43.54
- ICU 53.18
- Support Level
- AYTU $2.15
- ICU $0.76
- Resistance Level
- AYTU $2.28
- ICU $0.81
- Average True Range (ATR)
- AYTU 0.11
- ICU 0.07
- MACD
- AYTU -0.03
- ICU 0.01
- Stochastic Oscillator
- AYTU 16.07
- ICU 53.69
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.